David G. Menter, Ph.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
I am interested in the molecular and cellular biology of gastrointestinal tumors. These studies involve four primary areas of research: 1) to understand microenvironmental and age related effects of the colon stromal on CRC; 2) to examine the role of the stromal cell eicosanoid pathway and inflammatory pathway effects on CRC; 3) to examine the role of mesenchymal and epithelial stem cells in the development of CRC and 4) to develop mechanism based approaches of applying nanotechnology to cancer prevention. These studies involve isolating and characterizing cells from colon tumors as well as colon liver metastases. These cells will be used in co-culture experiments with colon tumor cells to examine the their ability to inhibit or promote the growth of tumor cells in vitro or in vivo. Further molecular and eicosanoid profiling will be performed co-cultured cells to dissect out the critical changes that occur when these cells interact during tumor formation. In the future, As a part of the age related effects of stromal cells on CRC, in the process of isolating normal colon and pancreatic mesenchymal and epithelial cells from various age wt or APCmin mice. These mesenchymal cells will be used in co-culture experiments with colon tumor cells to examine the effect of age or inflammatory bioactive lipids on the ability of mesenchymal cells to inhibit or promote the growth of tumor cells in vitro or in vivo.
Education & Training
Degree-Granting Education
| 1986 | Wayne State University, Detroit, MI, USA, PHD, Cell Biology |
| 1976 | Wayne State University, Detroit, MI, USA, BS, Biology |
Postgraduate Training
| 1986-1992 | Research Fellowship, Cell Biology, The University of Texas, Houston, TX |
Experience & Service
Academic Appointments
Assistant Professor, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2014
Administrative Appointments/Responsibilities
Administrative Director, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2014
Institutional Committee Activities
Chair, Institutional Animal Care and Use Committee, 2012 - Present
Committee Member, Animal Research Infrastructure Strategic Planning Committee, 2008 - Present
Member, User Committee for the Analytical Core of the UTMDACC Cancer Center Support Grant, 2005 - Present
Member, Institutional Animal Care and Use Committee, 1999 - Present
Honors & Awards
| 2002 | HSC Honors Convocation Recipient, University of Texas Health Science Center |
| 1998 | Flemming and Davenport Award, Texas Medical Center |
| 1997 | Shannon Award, National Cancer Institute |
| 1997 | Postdoctoral Support Award, Meadows Foundation |
| 1987 | Histopathobiology of Neoplasia Workshop, National Cancer Institute |
| 1986 | National Cancer Institute Postdoctoral Fellow in Human Genetics, National Cancer Institute |
| 1984 | Outstanding Researcher Award, Sigma Xi: The Scientific Research Society |
Selected Publications
Peer-Reviewed Articles
- Lin K, Chowdhury S, Zeineddine MA, Zeineddine FA, Hornstein NJ, Villarreal OE, Maru DM, Haymaker CL, Vauthey JN, Chang GJ, Bogatenkova E, Menter D, Kopetz S, Shen JP. Identification of colorectal cancer cell stemness from single-cell RNA sequencing. Mol Cancer Res. e-Pub 2023. PMID: 38156967.
- Ngo-Huang AT, Parker NH, Xiao L, Schadler KL, Petzel MQB, Prakash LR, Kim MP, Tzeng CD, Lee JE, Ikoma N, Wolff RA, Javle MM, Koay EJ, Pant SD, Folloder JP, Wang X, Cotto AM, Ju YR, Garg N, Wang H, Bruera ED, Basen-Engquist KM, Katz MHG. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. Ann Surg 278(1):22-30, 2023. e-Pub 2023. PMID: 37026453.
- Janku F, Javle MM, Sen S, Pant S, Bramwell LG, Subbiah V, Way T, Wages DS, Wheeler CA, Suzuki T, Saeki K, Subach RA, Madden T, Maier G, Johansen MJ, Cheung K, Falchook GS. A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. Cancer 129(10):1537-1546, 2023. e-Pub 2023. PMID: 36882377.
- Dodoo GN, De B, Lee SS, Abi Jaoude J, Vauthey JN, Tzeng CD, Tran Cao HS, Katlowitz KA, Mandel JJ, Beckham TH, Minsky BD, Smith GL, Holliday EB, Koong AC, Das P, Taniguchi CM, Javle M, Koay EJ, Ludmir EB. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist 28(4):327-332, 2023. PMID: 36715178.
- Ayabe RI, Paez-Arango N, Estrella JS, Newhook TE, Tzeng CD, Chun YS, Lee S, Javle M, Vauthey JN, Tran Cao HS. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma - does pathologic response mean better outcomes?. HPB (Oxford) 25(4):472-480, 2023. e-Pub 2023. PMID: 36781357.
- Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. Molecular Profiling and Treatment Pattern Differences between Intrahepatic and Extrahepatic Cholangiocarcinoma. J Natl Cancer Inst. e-Pub 2023. PMID: 37040087.
- Pant S, Dragovich T, Lieu C, Jimeno A, Kundranda M, Menter D, Tchaparian E, Chen YC, Kopetz S. Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. Invest New Drugs. e-Pub 2022. PMID: 36331676.
- Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
- Menter DG, Bresalier RS. An Aspirin a Day: New Pharmacological Developments and Cancer Chemoprevention. Annu Rev Pharmacol Toxicol. e-Pub 2022. PMID: 36202092.
- Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6. Cancer Res. e-Pub 2022. PMID: 35913398.
- Corvigno S, Johnson AM, Wong KK, Cho MS, Afshar-Kharghan V, Menter DG, Sood AK. Novel markers for liquid biopsies in cancer management: Circulating platelets and extracellular vesicles. Mol Cancer Ther 21(7):1067-1075, 2022. e-Pub 2022. PMID: 35545008.
- Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilie PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision combination therapies based on recurrent oncogenic co-alterations. Cancer Discov. e-Pub 2022. PMID: 35412613.
- Menter DG, Afshar-Kharghan V, Shen JP, Martch SL, Maitra A, Kopetz S, Honn KV, Sood AK. Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective. Cancer Metastasis Rev 41(1):147-172, 2022. e-Pub 2022. PMID: 35022962.
- Kanikarla Marie P, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, Woods MN, Anderson A, Capasso A, Fowlkes N, Overman MJ, Menter DG, Kopetz S. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol 12:994333, 2022. e-Pub 2022. PMID: 36212401.
- Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF, NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. Nat Commun 12(1):5086, 2021. e-Pub 2021. PMID: 34429404.
- Preeti Kanikarla Marie , Natalie W Fowlkes, Vahid Afshar-Kharghan, Stephanie L Martch, Alexey Sorokin, John Paul Shen, Van K Morris, Arvind Dasari , Nancy You, Anil K Sood, Michael J Overman , Scott Kopetz, David George Menter. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol 11:643815, 2021.
- Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: 33745946.
- Yusha Li , Keith A Baggerly , Elias Orouji , Ganiraju Manyam, Huiqin Chen , Michael Lam , Jennifer S Davis, Michael S Lee, Bradley M Broom , David G Menter , Kunal Rai , Scott Kopetz , Jeffrey S Morris. Methylation-eQTL Analysis in Cancer Research. Methylation-eQTL Analysis in Cancer Research:btab443, 2021. PMID: 34117863.
- Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
- Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, PDXNET Consortium, EurOPDX Consortium. Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53(5):761, 2021. PMID: 33608693.
- J. S. Morris, R. Luthra, Y. Liu, D. Y. Duose, W. Lee, N. G. Reddy, J. Windham, H. Chen, Z. Tong, B. Zhang, W. Wei, M. Ganiraju, B. M. Broom, H. A. Alvarez, A. Mejia, O. Veeranki, M. J. Routbort, V. K. Morris, M. J. Overman, D. Menter, R. Katkhuda, Wistuba, II, J. S. Davis, S. Kopetz and D. M. Maru,. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res 27(1):120-130, 2021.
- Woo XY, Giordano J, Srivastava A, Zhao ZM, Lloyd MW, de Bruijn R, Suh YS, Patidar R, Chen L, Scherer S, Bailey MH, Yang CH, Cortes-Sanchez E, Xi Y, Wang J, Wickramasinghe J, Kossenkov AV, Rebecca VW, Sun H, Mashl RJ, Davies SR, Jeon R, Frech C, Randjelovic J, Rosains J, Galimi F, Bertotti A, Lafferty A, O'Farrell AC, Modave E, Lambrechts D, Ter Brugge P, Serra V, Marangoni E, El Botty R, Kim H, Kim JI, Yang HK, Lee C, Dean DA, Davis-Dusenbery B, Evrard YA, Doroshow JH, Welm AL, Welm BE, Lewis MT, Fang B, Roth JA, Meric-Bernstam F, Herlyn M, Davies MA, Ding L, Li S, Govindan R, Isella C, Moscow JA, Trusolino L, Byrne AT, Jonkers J, Bult CJ, Medico E, Chuang JH, PDXNET Consortium, EurOPDX Consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53(1):86-99, 2021. e-Pub 2021. PMID: 33414553.
- Baoqing Chen, Mihnea P Dragomir, Linda Fabris , Recep Bayraktar, Erik Knutsen , Xu Liu , Changyan Tang , Yongfeng Li , Tadanobu Shimura, Tina Catela Ivkovic , Mireia Cruz De Los Santos, Simone Anfossi , Masayoshi Shimizu, Maitri Y Shah, Hui Ling, Peng Shen , Asha S Multani , Barbara Pardini, Jared K Burks , Hiroyuki Katayama , Lucas C Reineke, Longfei Huo , Muddassir Syed , Shumei Song, Manuela Ferracin, Eiji Oki, Bastian Fromm, Cristina Ivan, Krithika Bhuvaneshwar, Yuriy Gusev, Koshi Mimori, David Menter, Subrata Sen, Takatoshi Matsuyama, Hiroyuki Uetake , Catalin Vasilescu, Scott Kopetz, Jan Parker-Thornburg , Ayumu Taguchi, Samir M Hanash, Leonard Girnita, Ondrej Slaby , Ajay Goel, Gabriele Varani , Mihai Gagea , Chunlai Li , Jaffer A Ajani, George A Calin. The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. Gastroenterology 159(6):2146-2162, 2020.
- Jennifer S Davis, Preeti Kanikarla-Marie, Mihai Gagea, Patrick L Yu , Dexing Fang , Manu Sebastian, Peiying Yang, Ernest Hawk, Roderick Dashwood , Lenard M Lichtenberger , David Menter , Scott Kopetz. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 20(1):871, 2020.
- Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer 120(3):340-345, 2019. e-Pub 2019. PMID: 30636774.
- Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res 25(2):641-651, 2019. e-Pub 2018. PMID: 30352910.
- Zacharias NM, Ornelas A, Lee J, Hu J, Davis J, Uddin MN, Pudakalakatti S, Menter D, Karam JA, Wood CG, Hawk E, Kopetz S, Vilar E, Bhattacharya P, Millward S. Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy. Angew Chem Int Ed Engl. e-Pub 2019. PMID: 30680862.
- Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep 21(2):5, 2019. e-Pub 2019. PMID: 30701321.
- Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter DG, Ekmekcioglu S, Grimm EA. The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma. Clin Cancer Res. e-Pub 2018. PMID: 30538110.
- Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. PMID: 30112590.
- Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. e-Pub 2017. PMID: 28607096.
- Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. Cancer Cell 33(6):965-983, 2018. e-Pub 2018. PMID: 29657130.
- Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2017. PMID: 29180604.
- Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG. Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. Front Oncol 8:107, 2018. e-Pub 2018. PMID: 29732316.
- Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol 24(13):4051-4058, 2017. e-Pub 2017. PMID: 28936799.
- Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
- Katsiampoura A, Raghav K, Jiang ZQ, {bMenter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient-Derived Xenografts in Colorectal Cancer. Mol Cancer Ther 16(7):1435-1442, 2017. e-Pub 2017. PMID: 28468778.
- Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev 36(2):235-248, 2017. PMID: 28667367.
- Lam M, Roszik J, Kanikarla-Marie P, Davis JS, Morris J, Kopetz S, Menter DG. The potential role of platelets in the consensus molecular subtypes of colorectal cancer. Cancer Metastasis Rev 36(2):273-288, 2017. PMID: 28681242.
- Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, Honn KV. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev 36(2):199-213, 2017. PMID: 28730545.
- Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, Hawk E, Vilar E, Bhattacharya P, Millward S. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev 36(2):289-303, 2017. PMID: 28762014.
- Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. PMID: 28424412.
- Rigoutsos I, Lee SK, Nam SY, Anfossi S, Pasculli B, Pichler M, Jing Y, Rodriguez-Aguayo C, Telonis AG, Rossi S, Ivan C, Catela Ivkovic T, Fabris L, Clark PM, Ling H, Shimizu M, Redis RS, Shah MY, Zhang X, Okugawa Y, Jung EJ, Tsirigos A, Huang L, Ferdin J, Gafà R, Spizzo R, Nicoloso MS, Paranjape AN, Shariati M, Tiron A, Yeh JJ, Teruel-Montoya R, Xiao L, Melo SA, Menter D, Jiang ZQ, Flores ER, Negrini M, Goel A, Bar-Eli M, Mani SA, Liu CG, Lopez-Berestein G, Berindan-Neagoe I, Esteller M, Kopetz S, Lanza G, Calin GA. N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. Genome Biol 18(1):98, 2017. e-Pub 2017. PMID: 28535802.
- Lee MS, Menter DG, Kopetz S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. J Natl Compr Canc Netw 15(3):411-419, 2017. PMID: 28275039.
- Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol 28(3):468-477, 2017. PMID: 27998963.
- Whiting N, Hu J, Zacharias NM, Lokesh GL, Volk DE, Menter DG, Rupaimoole R, Previs R, Sood AK, Bhattacharya P. Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer. J Med Imaging (Bellingham) 3(3):036001, 2016. e-Pub 2016. PMID: 27547777.
- Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. e-Pub 2016. PMID: 27421137.
- Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell Melanoma Res 29(3):297-308, 2016. e-Pub 2016. PMID: 26801201.
- Umar A, Steele VE, Menter DG, Hawk ET. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 43(1):65-77, 2016. e-Pub 2015. PMID: 26970125.
- Fang L, Lu W, Choi HH, Yeung SC, Tung JY, Hsiao CD, Fuentes-Mattei E, Menter DG, Chen C, Wang L, Wang J, Lee MH. ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell 28(2):183-97, 2015. PMID: 26267535.
- Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
- Whiting N, Hu J, Shah JV, Cassidy MC, Cressman E, Zacharias Millward N, Menter DG, Marcus CM, Bhattacharya PK. Real-Time MRI-Guided Catheter Tracking Using Hyperpolarized Silicon Particles. Sci Rep 5:12842, 2015. e-Pub 2015. PMID: 26239953.
- Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet?. Cancer Prev Res (Phila) 7(10):973-92, 2014. e-Pub 2014. PMID: 25060262.
- Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RA. Cellular location and expression of Na+, K+ -ATPase α subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog 53(4):253-63, 2014. e-Pub 2012. PMID: 23073998.
- Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 33(1):231-69, 2014. PMID: 24696047.
- Menter DG, Dubois RN. Prostaglandins in Cancer Cell Adhesion, Migration, and Invasion. Int J Cell Biol 2012:723419, 2012. e-Pub 2012. PMID: 22505934.
- Holla VR, Wu H, Shi Q, Menter DG, DuBois RN. Nuclear Orphan Receptor NR4A2 Modulates Fatty Acid Oxidation Pathways in Colorectal Cancer. J Biol Chem 286(34):30003-9, 2011. e-Pub 2011. PMID: 21757690.
- Campbell SE, Rudder B, Phillips RB, Whaley SG, Stimmel JB, Leesnitzer LM, Lightner J, Dessus-Babus S, Duffourc M, Stone WL, Menter DG, Newman RA, Yang P, Aggarwal BB, Krishnan K. alpha-Tocotrienol induces growth arrest through a novel pathway with TGFbeta2 in prostate cancer. Free Radic Biol Med 50(10):1344-54, 2011. e-Pub 2011. PMID: 21335085.
- Kim SH, Xia D, Kim SW, Holla V, Menter DG, Dubois RN. Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res 70(10):4054-63, 2010. e-Pub 2010. PMID: 20442290.
- Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16(5):1384-90, 2010. e-Pub 2010. PMID: 20179228.
- Xia D, Holla VR, Wang D, Menter DG, DuBois RN. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res 70(2):824-31, 2010. e-Pub 2010. PMID: 20068165.
- Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa N, Newman RA. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol Cancer Ther 8(8):2319-28, 2009. e-Pub 2009. PMID: 19671733.
- Shin S, Asano T, Yao Y, Zhang R, Claret FX, Korc M, Sabapathy K, Menter DG, Abbruzzese JL, Reddy SA. Activator protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel Akt-mediated mechanism. Mol Cancer Res 7(5):745-54, 2009. PMID: 19435822.
- Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 2009. PMID: 19244175.
- Jin Q, Menter DG, Mao L, Hong WK, Lee HY. Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis 29(8):1614-22, 2008. PMID: 18635526.
- Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res 12:2178-84, 2006. PMID: 16609032.
- Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma. Oncogene 25:6015-25, 2006. PMID: 16682954.
- Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7:280-93, 2005. PMID: 15799828.
- Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65:6189-98, 2005. PMID: 16024620.
- Sabichi AL, Subbarayan V, Llansa N, Lippman SM, Menter DG. PPARg suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers and Prev 13:1704-9, 2004.
- Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279:19191-200, 2004. PMID: 14985354.
- Yang P, Chan D, Felix E, Cartwright C, Menter DG, Madden T, Klein RD, Fischer SM, Newman RA. Formation and antiproliferative effect of prostaglandin E(3) from eicosapentaenoic acid in human lung cancer cells. J Lipid Res 45:1030-9, 2004. PMID: 14993240.
- Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13:1710-6, 2004. PMID: 15533897.
- Xu X, CShappell SB, Liang Z, Song S, Menter DG, Subbarayan V, Iyengar S, Tang DG, Lippman SM. Reduced 15-S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. Neoplasia 5:121-7, 2003.
- Salas TR, Reddy SA, Clifford JL, Davis RJ, Kikuchi A, Lippman SM, Menter DG. Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 278:41338-46, 2003. PMID: 12900420.
- Menter DG. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Drugs 11(12):1749-64, 2002. PMID: 12457435.
- Hoque A, Sneige N, Sahin AA, Menter DG, Bacus JW, Hortobagyi GN, Lippman SM. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 11:587-90, 2002. PMID: 12050101.
- Hoque A, Menter DG, Sahin AA, Sneige N, Lippman SM. No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 10:153-4, 2001. PMID: 11219775.
- Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 61:2720-6, 2001. PMID: 11289153.
- Menter DG, Hoque A, Motiwala N, Sahin AA, Sneige N, Lieberman R, Lippman SM. Computerized image analysis of Ki-67 in ductal breast carcinoma in situ (DCIS). Anal Quant Cytol Histol 23:218-28, 2001. PMID: 11444192.
- Schaefer LK, Menter DG, Schaefer TS. Activation of stat3 and stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines. Cell Signal 12:143-51, 2000. PMID: 10704821.
- Papadimitriou MN, McIntire LV, Menter DG. Effect of cyclooxygenase inhibitors in the adhesion of tumor cells to endothelial cells. Crit Rev Biomed Eng 28:193-4, 2000. PMID: 10999385.
- Clifford JL, Menter DG, Yang X, Walch E, Zou C, Clayman GL, Schaefer TS, El-Naggar AK, Lotan R, Lippman SM. Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 9:993-7, 2000. PMID: 11008921.
- Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 9:1171-82, 2000. PMID: 11097224.
- Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 59:14-8, 1999. PMID: 9892176.
- Papadimitriou MN, Menter DG, Konstantopoulos K, Nicolson GL, McIntire LV. Integrin alpha4beta1/VCAM-1 pathway mediates primary adhesion of RAW117 lymphoma cells to hepatic sinusoidal endothelial cells under flow. Clin Exp Metastasis 17:669-76, 1999. PMID: 10919712.
- Herrmann JL, Menter DG, Beham A, von Eschenbach A, McDonnell TJ. Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. Exp Cell Res 234:442-51, 1997. PMID: 9260915.
- Smith TW, Yun Z, Menter DG, McIntire LV, Nicolson GL. Computerized analysis of tumor cell interactions with extracellular matrix proteins, peptides and endothelial cells under laminar flow. Biotechnol. Bioengineer 50:598-607, 1996.
- Smith TW, Menter DG, Nicolson GL, McIntire LV. Signaling mechanisms in stabilization of melanoma adhesion. Melanoma Research 6:351-62, 1996.
- Yun Z, Menter DG, Nicolson GL. Involvement of integrin alphavbeta3 in cell adhesion, motility, and liver metastasis of murine RAW117 large cell lymphoma. Cancer Res 56:3103-11, 1996. PMID: 8674068.
- Nicolson GL, Menter DG, Herrmann JL, Yun Z, Cavanaugh P, Marchetti D. Brain metastasis: role of trophic, autocrine, and paracrine factors in tumor invasion and colonization of the central nervous system. Curr Top Microbiol Immunol 213 ( Pt 2):89-115, 1996. PMID: 9053298.
- Menter DG, Herrmann JL, Nicolson GL. The role of trophic factors and autocrine/paracrine growth factors in brain metastasis. Clin Exp Metastasis 13:67-88, 1995. PMID: 7882617.
- Menter DG, Fitzgerald L, Patton JT, McIntire LV, Nicolson GL. Human melanoma integrins contribute to arrest and stabilization potential while flowing over extracellular matrix. Immunol Cell Biol 73:575-83, 1995. PMID: 8713481.
- Nicolson GL, Menter DG. Trophic factors and central nervous system metastasis. Cancer Metastasis Rev 14:303-21, 1995. PMID: 8821092.
- Menter, DG, Gundlach, N, Steinert, BW, Diglio, C, Walz, D, Sloane, B F, Taylor, JD, Honn, KV. Platelet enhancement of tumor cell adhesion to endothelial cell extracellular matrix. Cancer Res 47:6751-62, 1987.
- Kim S, Hashimoto Y, Cho S, Roszik J, Milton D, Dal F, Kim S, Menter D, Yang P, Ekmekcioglu S, Grimm E. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell and Melanoma. Pigment Cell and Melanoma.
Invited Articles
- Umar A, Steele V, Menter DG, Hawk E. Mechanisms of Non-steroidal Anti-inflammatory Drugs (NSAIDs) In Cancer Prevention. Seminars in Oncology.
Book Chapters
- Menter DG, Davis JS, Tucker SC, Hawk E,, Crissman JD, Kopetz S, Honn KV. Platelets: "First Responders". In: Cancer Progression and Metastasis.
Grant & Contract Support
| Title: | Link Between IGF-1 Receptor Signaling, Akt, and Androgen Receptor(AR) and Development of a Rationale for Combination Therapies in Prostate Cancer |
| Funding Source: | CAPCURE |
| Role: | Co-Investigator |
| Title: | Nuclear Hormone Receptors and Intestinal Epithelial Biology |
| Funding Source: | NIH/NIDDK |
| Role: | Investigator |
| Title: | Role of Eicosanoids in Intestinal Epithelial Growth and Function |
| Funding Source: | NIH/NIDDK |
| Role: | Investigator |
| Title: | Prostaglandins and Inflammation in Colorectal Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator-MDACC |
| Title: | Novel prostaglandin E2 pathway targeted drugs for colorectal cancer |
| Funding Source: | CRC Moon Shot |
| Role: | Principal Investigator |
| Title: | CRC-Moon Shot |
| Funding Source: | CRC Moon Shot |
| Role: | Co-Investigator |
| Title: | Advanced Approaches to Understanding and Targeting BRAF Tumors |
| Funding Source: | Gastro-Intestinal Research Foundation |
| Role: | Co-Principal Investigator |
| Title: | Epigenetic mechanism and targeting during response to BRAFi/anti-EGFR therapy in BRAF-mutant colorectal cancers |
| Funding Source: | NIH |
| Role: | Co-Investigator |
| Title: | Epigenetic mechanism and targeting during response to BRAF/anti-EGFR therapy in BRAF-mutant colorectal cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Colorectal Cancer Biology and Risk among African Americans |
| Funding Source: | Sub w University of Kansas Medical Center |
| Role: | Co-Investigator |
| Title: | Colorectal Cancer Molecular Subtype Assay Development and Validation |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | Overcoming adaptive resistance to KRAS inhibition in CRC |
| Funding Source: | National Institutes of Health – NIH (Pass Thru Sponsor) Massachusetts General Hospital) |
| Role: | Co-Investigator |
| Title: | INTERCEPT - Colorectal Cancer Research |
| Funding Source: | E.L. and Thelma Gaylord Foundation |
| Role: | Co-Investigator |
| Title: | Targeting adaptive and acquired resistance to direct KRAS inhibition |
| Funding Source: | Stand up to Cancer – Mirati Subaward with Massachusetts General Hospital |
| Role: | Scientific Manager |
| Title: | Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer: Project 3 |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| Title: | University of Texas PDX Development and Trial Center |
| Funding Source: | NCI |
| Role: | Co-Investigator |
| Title: | University of Texas PDX Development and Trial Center |
| Funding Source: | NIH |
| Role: | Co-Investigator |
Patient Reviews
CV information above last modified January 08, 2024